A

Amgen

Biotech company creating biologic medicines

Clean Utilities Senior Engineer

Full-TimeUpdated on 10/4/2026Deadline 10/15/26
$115.5k - $156.3k+ Discretionary annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's, PhD, Associate's
Holly Springs, NC, USA
In Person

About the job

Requirements
  • A high school diploma or GED and 10 years of engineering or maintenance experience, or an associate’s degree and 8 years of engineering or maintenance experience, or a bachelor’s degree and 4 years of engineering or maintenance experience, or a master’s degree and 2 years of engineering or maintenance experience, or a doctorate degree.
  • A bachelor’s degree in Chemical, Mechanical, or Electrical Engineering is preferred.
  • At least 4 years of relevant work experience, including 2 years in a biopharmaceutical operations or manufacturing environment, is preferred.
  • Direct knowledge of design and troubleshooting with GMP biopharmaceutical production facility utility equipment and systems, including pharmaceutical water, clean steam, and clean air generation and distribution, as well as plant utility equipment such as chilled-water chillers, cooling towers, steam boilers, and air compressors, is preferred.
  • Experience with equipment and facility control systems operation, logic, and troubleshooting is preferred.
  • Ability to analyze problems and develop and propose engineering solutions scientifically using data-driven techniques and analyses, such as data analytics, root cause analysis, statistical process control, Six Sigma, and predictive maintenance, is preferred.
  • Experience working in a regulated environment, such as cGMP, OSHA, or EPA, and familiarity with GMP quality systems and processes such as change control, non-conformances, corrective and preventive actions, and qualifications or validation, are preferred.
  • Experience applying engineering principles to design and implement system modifications, introduce new processes, and execute capital projects is preferred.
  • Understanding of capital-project execution in a GMP biopharmaceutical production facility, including procurement, construction, startup, and validation, is preferred.
  • Understanding of safety requirements for work in a GMP biopharmaceutical production facility is preferred.
  • Work-schedule flexibility to support 24/7 operations, including occasional after-hours engineering coverage, is preferred.
  • Ability to travel domestically and internationally is preferred.
Responsibilities
  • Provide system ownership for clean and plant utility systems and equipment supporting site operations.
  • Provide engineering support for the design, construction, startup, commissioning, and qualification of new or modified systems.
  • Identify, support, and/or lead implementation of engineering-based improvements or upgrades of small to medium scope and complexity to equipment or facility systems, and lead development of a business case when required to support project completion.
  • Develop equipment maintenance programs, ensure spare-parts availability, and coordinate maintenance execution as necessary to keep systems in proper working order.
  • Ensure systems are safely installed and operated and comply with relevant environmental, health, and safety practices, rules, and regulations.
  • Ensure commissioning and qualification of systems are completed in alignment with GMP requirements and interact with regulatory inspectors as necessary.
  • Apply basic engineering principles and practices to support daily operation, maintenance, and troubleshooting of plant systems.
  • Monitor systems to identify performance risks and implement risk-reduction strategies.
  • Provide troubleshooting support to reduce production downtime, including leading and/or supporting technical root-cause analysis and implementing corrective and preventive actions.
  • Support new product and technology introductions by performing engineering assessments, implementing equipment modifications, and supporting engineering runs.
  • Advance condition-based and predictive maintenance practices by incorporating advanced data analytics where applicable.
  • Own investigations of abnormal conditions through deviation and business processes.
Desired Qualifications
  • A bachelor’s degree in Chemical, Mechanical, or Electrical Engineering.
  • At least 4 years of relevant work experience, including 2 years in a biopharmaceutical operations or manufacturing environment.
  • Direct knowledge of design and troubleshooting with GMP biopharmaceutical production facility utility equipment and systems, including pharmaceutical water, clean steam, and clean air generation and distribution, as well as plant utility equipment such as chilled-water chillers, cooling towers, steam boilers, and air compressors.
  • Experience with equipment and facility control systems operation, logic, and troubleshooting.
  • Ability to analyze problems and develop and propose engineering solutions scientifically using data-driven techniques and analyses, such as data analytics, root cause analysis, statistical process control, Six Sigma, and predictive maintenance.
  • Experience working in a regulated environment, such as cGMP, OSHA, or EPA, and familiarity with GMP quality systems and processes such as change control, non-conformances, corrective and preventive actions, and qualifications or validation.
  • Experience applying engineering principles to design and implement system modifications, introduce new processes, and execute capital projects.
  • Understanding of capital-project execution in a GMP biopharmaceutical production facility, including procurement, construction, startup, and validation.
  • Understanding of safety requirements for work in a GMP biopharmaceutical production facility.
  • Work-schedule flexibility to support 24/7 operations, including occasional after-hours engineering coverage.
  • Ability to travel domestically and internationally.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $39.4 billion.
  • Imdelltra sales jumped 219% year over year in Q1 2026, signaling rapid launch traction.
  • Repatha sales rose 37% in Q2 2026, driven by expanding cardiology and primary-care adoption.

What critics are saying

  • Prolia and Enbrel face accelerating biosimilar erosion; Amgen expects continued sales declines through 2026.
  • Three distributors generated 77% of gross revenue in 2026, concentrating pricing leverage brutally.
  • MariTide failure would crater obesity optionality and expose Amgen's growth to aging franchises.

What makes Amgen unique

  • September 2026 Imdelltra-IMFINZI phase III hit overall survival in first-line ES-SCLC.
  • August 2026 Repatha reduced death risk in high-risk patients, strengthening Amgen's cardiovascular moat.
  • MariTide's monthly-or-less dosing and nine Phase III studies separate it from weekly GLP-1s.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.